Drug Trial News

RSS

Takeda unbinds Phase 3 study of orteronel in patients with mCRPC that progressed post-chemotherapy

Takeda Pharmaceutical Company Limited ("Takeda") announced today that it has unblinded the ELM-PC 5 Phase 3 study (C21005) of orteronel plus prednisone compared to placebo plus prednisone in patients with metastatic, castration- resistant prostate cancer (mCRPC) that had progressed during or following chemotherapy based on the recommendation of the Independent Data Monitoring Committee (IDMC).

26 Jul 2013

NOXXON completes patient recruitment of NOX-E36 Phase IIa trial for treatment of diabetic nephropathy

NOXXON Pharma today announced the successful completion of patient recruitment of its NOX-E36 Phase IIa clinical trial for the treatment of diabetic nephropathy. NOX-E36 is a Spiegelmer® that binds and neutralizes CCL2/MCP-1 (C-C Chemokine Ligand / Monocyte Chemoattractant Protein-1), a pro-inflammatory chemokine that plays an important role in the progression of diabetic nephropathy, the most common single cause of chronic kidney failure and end-stage renal disease.

25 Jul 2013

Randomized trial examines purging of tumor cells from stem cells prior to transplantation in neuroblastoma patients

Judith Villablanca, MD, of The Saban Research Institute of Children's Hospital Los Angeles, Susan Kreissman, MD, of Duke University Medical Center, and colleagues reported the results of a randomized, phase 3 clinical trial conducted by the Children's Oncology Group examining the effect of selectively removing (purging) tumor cells from blood stem cells before they are transplanted back into patients with high-risk neuroblastoma following high-dose chemotherapy.

25 Jul 2013

Inovio plans to advance synthetic hTERT cancer vaccine into clinical trials in 2014

Inovio Pharmaceuticals, Inc. announced today that in a preclinical study with two animal models, Inovio's hTERT (human telomerase reverse transcriptase) DNA cancer vaccine administered with Inovio's CELLECTRA adaptive electroporation delivery technology generated robust and broad immune responses, broke the immune system's tolerance to its self-antigens, induced T-cells with a tumor-killing function, and increased the rate of survival.

24 Jul 2013

Genentech announces that Phase III CLL11 study meets primary endpoint

Genentech, a member of the Roche Group, today announced positive results from the Phase III CLL11 study. At a pre-planned interim analysis, an independent data monitoring committee determined that the study met its primary endpoint showing that GA101 plus chlorambucil helped people live significantly longer without their disease worsening (progression-free survival; PFS) compared to Rituxan (rituximab) plus chlorambucil.

24 Jul 2013

Prana Biotechnology completes PBT2 phase 2 trial in patients with Huntington's disease

Prana Biotechnology today announced the successful completion of Reach2HD, a phase 2 clinical trial in patients with early to mid-stage Huntington disease. The Company expects to announce the results arising from the trial in October.

23 Jul 2013

Array BioPharma announces positive results from ARRY-502 Phase 2 trial for allergic asthma

Array BioPharma Inc. today announced positive results from a placebo-controlled, randomized, double‑blind Phase 2 trial in mild to moderate persistent allergic asthma for ARRY-502, an oral CRTh2 antagonist.

23 Jul 2013

Serum Institute of India secures license to patents, technologies related to tuberculosis vaccine

Hopes are high for a new and improved tuberculosis vaccine: Serum Institute of India is planning on taking a promising vaccine - originally developed in Germany - and introducing it into the clinical setting.

23 Jul 2013

Imprimis to begin IRB-approved Impracor Phase III trial for acute pain associated with OA of the knee

Imprimis Pharmaceuticals, Inc., which is focused on the commercialization of compounded drug formulations utilizing the FDA 505(b)(2) development pathway, today announced it has received IRB approval for its Phase III clinical trial protocol of its lead product candidate, Impracor.

23 Jul 2013

BioCryst completes BCX4161 Phase 1 clinical trial for treatment of hereditary angioedema

BioCryst Pharmaceuticals, Inc. announced that the randomized, placebo-controlled, Phase 1 clinical trial of orally-administered BCX4161 in healthy volunteers successfully met all of its objectives.

22 Jul 2013

IVAN study: Lucentis and Avastin effective in treating wet AMD

An anti-cancer drug has been proven to be equally as effective in treating the most common cause of blindness in older adults as a more expensive drug specifically formulated for this purpose.

20 Jul 2013

Phase 2 EORTC trial shows moderate dose radiotherapy is effective in desmoid-type fibromatosis patients

A phase 2 EORTC trial for patients with inoperable desmoid-type fibromatosis has shown that moderate dose radiotherapy is an effective treatment for patients with such a rare type of tumor. The study results published in Annals of Oncology show that response after radiation therapy is slow, and that continuing regression is seen even after three years.

19 Jul 2013

Anacor presents Phase 3 safety and efficacy results of Tavaborole for treatment of onychomycosis

Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that its abstract "Pivotal Phase 3 Safety and Efficacy Results of Tavaborole (Formerly AN2690), a Novel Boron-Based Molecule for the Topical Treatment of Toenail Onychomycosis" was accepted for oral presentation at the 2013 APMA Annual Scientific Meeting (The National) to be held in Las Vegas, Nevada.

19 Jul 2013

Cubist initiates bevenopran Phase 3 studies in patients with chronic non-cancer pain and OIC

Cubist Pharmaceuticals, Inc. today announced the initiation of Phase 3 efficacy studies of bevenopran (previously known as CB-5945) in patients with chronic non-cancer pain and opioid-induced constipation.

19 Jul 2013

FDA approves Janssen Biotech's SIMPONI ARIATM for infusion for active rheumatoid arthritis

Janssen Biotech, Inc. announced today the U.S. Food and Drug Administration approval of SIMPONI ARIATM (golimumab) for infusion for the treatment of adults with moderately to severely active rheumatoid arthritis in combination with methotrexate.

19 Jul 2013

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Celgene Corporation today announced that after consultation with the U.S. Food and Drug Administration Celgene will discontinue treatment with REVLIMID (lenalidomide) in the open-label, phase III ORIGIN trial, which enrolled 450 patients in over 100 sites in 26 countries.

18 Jul 2013

Ablynx initiates additional Phase I studies with anti-RSV Nanobody ALX-0171

Activaero GmbH, the therapeutic area specialist for respiratory diseases focusing on novel, pharmacoeconomically meaningful treatment solutions, today announced that its partner Ablynx NV has initiated additional Phase I studies with its anti-RSV Nanobody ALX-0171 using Activaero's FAVORITE inhalation approach.

18 Jul 2013

Drug that spurs cancer cells to self-destruct is on road to human clinical trials

Thanks to a new $2 million investment, a drug that spurs cancer cells to self-destruct while sparing healthy cells is on the road to human clinical trials. The compound, known as PAC-1, has so far proven safe and has promising anti-cancer effects in cell culture, in mouse models of cancer and in pet dogs with spontaneously occurring lymphomas and osteosarcomas.

18 Jul 2013

Common elderberry could be remedy for travellers susceptible to cold and flu, say researchers

The common elderberry could be just the remedy for international travellers susceptible to colds and bugs, according to researchers from the Griffith Health Institute.

17 Jul 2013

OncoGenex completes enrollment in OGX-427 Phase 2 trial for treatment of metastatic bladder cancer

OncoGenex Pharmaceuticals, Inc. today announced that enrollment has been completed in Borealis-1, a company-sponsored, randomized, placebo-controlled Phase 2 trial of OGX-427 in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.

16 Jul 2013

Drug Trial News

Takeda unbinds Phase 3 study of orteronel in patients with mCRPC that progressed post-chemotherapy

NOXXON completes patient recruitment of NOX-E36 Phase IIa trial for treatment of diabetic nephropathy

Randomized trial examines purging of tumor cells from stem cells prior to transplantation in neuroblastoma patients

Inovio plans to advance synthetic hTERT cancer vaccine into clinical trials in 2014

Genentech announces that Phase III CLL11 study meets primary endpoint

Prana Biotechnology completes PBT2 phase 2 trial in patients with Huntington's disease

Array BioPharma announces positive results from ARRY-502 Phase 2 trial for allergic asthma

Serum Institute of India secures license to patents, technologies related to tuberculosis vaccine

Imprimis to begin IRB-approved Impracor Phase III trial for acute pain associated with OA of the knee

BioCryst completes BCX4161 Phase 1 clinical trial for treatment of hereditary angioedema

IVAN study: Lucentis and Avastin effective in treating wet AMD

Phase 2 EORTC trial shows moderate dose radiotherapy is effective in desmoid-type fibromatosis patients

Anacor presents Phase 3 safety and efficacy results of Tavaborole for treatment of onychomycosis

Cubist initiates bevenopran Phase 3 studies in patients with chronic non-cancer pain and OIC

FDA approves Janssen Biotech's SIMPONI ARIATM for infusion for active rheumatoid arthritis

Celgene to discontinue treatment with REVLIMID in phase III ORIGIN trial

Ablynx initiates additional Phase I studies with anti-RSV Nanobody ALX-0171

Drug that spurs cancer cells to self-destruct is on road to human clinical trials

Common elderberry could be remedy for travellers susceptible to cold and flu, say researchers

OncoGenex completes enrollment in OGX-427 Phase 2 trial for treatment of metastatic bladder cancer

How does norepinephrine influence anxiety-related behaviours?

Transforming Lab Workflows with Cell Culture Automation

Building Bridges to Scalable Allogeneic Cell Therapy

Latest News